Wirtz Andrea L, Weir Brian Wilson, Mon Sandra Hsu Hnin, Sirivongrangson Pachara, Chemnasiri Tareerat, Dunne Eileen F, Varangrat Anchalee, Hickey Andrew C, Decker Michele R, Baral Stefan, Okanurak Kamolnetr, Sullivan Patrick, Valencia Rachel, Thigpen Michael C, Holtz Timothy H, Mock Philip A, Cadwell Betsy, Adeyeye Adeola, Rooney James F, Beyrer Chris
Center for Public Health and Human Rights, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Department of Health, Behavior & Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
JMIR Res Protoc. 2020 Jan 27;9(1):e15354. doi: 10.2196/15354.
Pre-exposure prophylaxis (PrEP) is highly effective in the prevention of HIV acquisition, particularly for men who have sex with men (MSM). Questions remain on the benefits of PrEP and implementation strategies for those at occupational risk of HIV acquisition in sex work, as well as on methods to support adherence among young people who initiate PrEP.
The Combination Prevention Effectiveness study for young cisgender MSM and transgender women (TGW) aims to assess the effectiveness and cost-effectiveness of a combination intervention among HIV-uninfected young MSM and TGW engaged in sex work in Thailand.
This open-label, nonrandomized assessment compares the relative effectiveness of a combination prevention intervention with and without daily oral emtricitabine and tenofovir disoproxil fumarate (Truvada) PrEP with SMS-based adherence support. HIV-uninfected young MSM and TGW aged 18 to 26 years in Bangkok and Pattaya who self-report selling/exchanging sex at least once in the previous 12 months are recruited by convenience sampling and peer referral and are eligible regardless of their intent to initiate PrEP. At baseline, participants complete a standard assessment for PrEP eligibility and may initiate PrEP then or at any time during study participation. All participants complete a survey and HIV testing at baseline and every 3 months. Participants who initiate PrEP complete monthly pill pickups and may opt-in to SMS reminders. All participants are sent brief weekly SMS surveys to assess behavior with additional adherence questions for those who initiated PrEP. Adherence is defined as use of 4 or more pills within the last 7 days. The analytic plan uses a person-time approach to assess HIV incidence, comparing participant time on oral PrEP to participant time off oral PrEP for 12 to 24 months of follow-up, using a propensity score to control for confounders. Enrollment is based on the goal of observing 620 person-years (PY) on PrEP and 620 PY off PrEP.
As of February 2019, 445 participants (417 MSM and 28 TGW) have contributed approximately 168 PY with 95% (73/77) retention at 12 months. 74.2% (330/445) of enrolled participants initiated PrEP at baseline, contributing to 134 PY of PrEP adherence, 1 PY nonadherence, and 33 PY PrEP nonuse/noninitiation. Some social harms, predominantly related to unintentional participant disclosure of PrEP use and peer stigmatization of PrEP and HIV, have been identified.
The majority of cisgender MSM and TGW who exchange sex and participate in this study are interested in PrEP, report taking sufficient PrEP, and stay on PrEP, though additional efforts are needed to address community misinformation and stigma. This novel multilevel, open-label study design and person-time approach will allow evaluation of the effectiveness and cost-effectiveness of combination prevention intervention in the contexts of both organized sex work and exchanged sex.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR1-10.2196/15354.
暴露前预防(PrEP)在预防艾滋病毒感染方面非常有效,特别是对于男男性行为者(MSM)。关于PrEP对从事性工作有职业性艾滋病毒感染风险者的益处和实施策略,以及支持开始PrEP的年轻人坚持用药的方法,仍存在疑问。
针对年轻的顺性别男男性行为者和跨性别女性(TGW)的联合预防有效性研究旨在评估在泰国从事性工作的未感染艾滋病毒的年轻男男性行为者和跨性别女性中,一种联合干预措施的有效性和成本效益。
这项开放标签、非随机评估比较了联合预防干预措施(有或没有每日口服恩曲他滨和替诺福韦酯富马酸盐(Truvada)PrEP并辅以基于短信的坚持用药支持)的相对有效性。通过便利抽样和同伴推荐,招募曼谷和芭堤雅年龄在18至26岁、自我报告在过去12个月内至少有过一次性交易的未感染艾滋病毒的年轻男男性行为者和跨性别女性,无论其是否打算开始PrEP均符合条件。在基线时,参与者完成PrEP资格的标准评估,可在此时或研究参与期间的任何时间开始PrEP。所有参与者在基线时以及每3个月完成一次调查和艾滋病毒检测。开始PrEP的参与者每月领取药丸,并可选择接收短信提醒。向所有参与者发送每周简短的短信调查,以评估行为,并向开始PrEP的参与者提出额外的坚持用药问题。坚持用药定义为在过去7天内服用4片或更多药丸。分析计划采用人时方法评估艾滋病毒发病率,在12至24个月的随访中,将参与者口服PrEP的时间与未口服PrEP的时间进行比较,使用倾向评分控制混杂因素。入组基于在PrEP上观察620人年(PY)和不在PrEP上观察620 PY的目标。
截至2019年2月,445名参与者(417名男男性行为者和28名跨性别女性)贡献了约168 PY,12个月时的保留率为95%(73/77)。74.2%(330/445)的入组参与者在基线时开始PrEP,贡献了134 PY的PrEP坚持用药时间、1 PY的不坚持用药时间和33 PY的未使用/未开始PrEP时间。已发现一些社会危害,主要与参与者无意中透露PrEP使用情况以及同伴对PrEP和艾滋病毒的污名化有关。
大多数参与本研究的从事性交易的顺性别男男性行为者和跨性别女性对PrEP感兴趣,报告服用了足够的PrEP并持续使用,但仍需要额外努力来解决社区中的错误信息和污名化问题。这种新颖的多层次、开放标签研究设计和人时方法将允许评估在有组织的性工作和性交易背景下联合预防干预措施的有效性和成本效益。
国际注册报告识别码(IRRID):RR1-10.2196/15354。